The parameters set in the experiment under two models. by Xiying Wang (4859998)

Subjects:

Validation results for the different scenario parameter sets and the resulting KGE_mean value. by Fabian Mitze (21084251)

Boxplots comparing KGE_mean values of every scenario setting (a-e) for validation, where the filled black dot symbolizes the mean. by Fabian Mitze (21084251)

Accuracy and loss of LSTM model training and testing. by Leijie Wang (21485157)

The decreased permeability caused by phospholipid content in the membrane could drive the emergence of other functions in the protocells. by Wentao Ma (326530)

Parameter sets generated through Latin hypercube sampling. by Alexandra M. Campbell (3284094)

Subjects:

A list of studies used to generate the wall thickness distribution via the probabilistic model together with evaluated mean wall thickness and mean undeformed wall thickness using... by Jan Kracík (20370911)

Subjects:

Distribution of final population size (A) and mean change in mean MSI over time (B) over 100 simulations for each parameter set shown in Table 3 in the absence of weevils (left) an... by Alexandra M. Campbell (3284094)

Subjects:

Minimal data set. by Salomé Mascarell (20234689)

Results of multiple logistic regression analysis to identify potential factors associated with the successful reduction of HPC and F+ coliphage in the POU UVC LED effluent. Single... by Hania Zanib (21864477)

Setting of experimental environment and model parameters. by Guozhu Sui (21672798)

Average mean decrease Gini across 100 partitions for the top 10 most important variables for binary mixed model and random forest. by Helal El-Zaatari (20442243)

“…<p>Average mean decrease Gini across 100 partitions for the top 10 most important variables for binary mixed model and random forest.…”

WT data of set A398E/V and set M1425V/I pooled for better comparison. by Yousra El Ghaleb (22075892)

Lymphocytes decreased in mouse pneumonia model. by Qi Xu (134661)

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Clinical features and cancer treatment in patients with breast cancer receiving letrozole and anastrozole. by Kazuyoshi Ohkawa (836847)

Subjects:

S1 Data - by Kazuyoshi Ohkawa (836847)

Subjects: